ARRIVENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 77.83K shares, a 276.39% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 31.20K shares, a 55.29% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 12.35K shares, a 0.47% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 22.80K shares, a 87.69% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 125.61K shares, a 41.15% decline from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 213.42K shares, a 37.58% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 155.13K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 77.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 144.18K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 31.20K shares 10-Q · filed 2026-05-11 | 87.03K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 12.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 125.61K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 22.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 125.66K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 20.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 288.13K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 69.77K shares 10-Q · filed 2025-05-12 | 282.79K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 12.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 213.42K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 185.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2024-06-30 | 15.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | |
| 2024-03-31 | 409.00 shares 10-Q · filed 2024-05-08 | |
| 2023-12-31 | 155.13K shares 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |